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Abstract In this study, we characterised the mechanisms of Rac
GTPase activation in human platelets stimulated by two
physiological agonists, either thrombin, acting through mem-
brane receptors coupled to heterotrimeric G-proteins, or collagen
which is known to mobilise a tyrosine kinase-dependent pathway.
Both agonists induced a rapid activation of Rac that was not
significantly affected by the inhibition of integrin KIIbL3
engagement. Using pharmacological inhibitors, we found that
phospholipase C activation and calcium mobilisation were
essential for platelet Rac activation by either thrombin or
collagen whereas protein kinase C inhibition was without effect.
In contrast to Rac, Cdc42 activation was independent of
phospholipase C activation, indicating that the two GTPases
are differently regulated. We also found that phosphoinositide
3-kinase was not required for Rac activation in response to
thrombin but was involved in its activation by collagen. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The actin cytoskeleton undergoes dramatic reorganisation
during blood platelet activation and is essential for platelet
shape change resulting in ¢lopod formation, lamellar exten-
sion and cell spreading [1,2]. The temporal sequences of actin
remodelling in platelets activated by various agonists make
these cells useful for investigating the role and the regulation
of the Rho family of small GTPases, which plays a critical
role in the control of actin cytoskeleton dynamics [3^5].
RhoA, Rac and Cdc42 are strongly expressed in platelets [6]
but their role in the di¡erent phases of platelet activation
remains poorly characterised. Using permeabilised human
platelets and exogenous active GTPases, it has been shown
that Rac can play a major role in phosphatidylinositol 4,5-
bisphosphate production and actin ¢lament barbed-end un-
capping leading to actin assembly [7,8]. Recently, Azim et
al. [9] have clearly shown that both Rac and Cdc42 are indeed
rapidly stimulated upon ligation of the thrombin receptor pro-
teinase-activated receptor-1 (PAR1). However, the mecha-
nisms by which Rho GTPases become activated through
G-protein-coupled receptors in platelets are still unclear. In
other cells, G-protein-coupled receptor-mediated activation
of Rac has been shown to involve Gi-type G-proteins [10^
12]. In endothelial cells, the G-protein LQ-subunits appear to
be involved in this mechanism as well as phosphoinositide
3-kinase (PI 3-kinase) [11,12]. Receptors triggered by throm-
bin couple to Gi, Gq and G12/G13 [13] and are able to rapidly
recruit and/or activate several e¡ectors such as phospholipase
C (PLC), protein kinase C (PKC) or PI 3-kinase. In this
study, we investigated the role of these key signalling enzymes
in the process of GTP charging of Rac in response to throm-
bin. Moreover, since the recruitment of Rac downstream
platelet receptors that directly stimulate tyrosine kinases re-
mains poorly understood, we also characterised its activation
by collagen, an agonist known to rapidly activate tyrosine
kinases, mainly through its receptor GpVI [14].
By direct quanti¢cation of GTP-Rac, we found that this
small GTPase became rapidly activated by both thrombin
and collagen in an integrin KIIbL3-independent manner. In
both cases, PLC activity and an increase in intracellular
Ca2 concentration were required, whereas PKC inhibition
was without e¡ect. Interestingly, PLC was not required for
Cdc42 activation. Finally, we showed that PI 3-kinase was
involved in the activation process of Rac only by collagen.
2. Materials and methods
2.1. Materials
Human K-thrombin was purchased from Enzyme Research Labo-
ratories and collagen from Nycomed Arzneimittel (Germany). RO 31-
8220 and U-73122 were from Calbiochem. SR121566 and C7E3 Fab
fragments (abciximab, ReoPro) were kindly provided by Dr P. Savi
(Sano¢-Synthelabo, Toulouse, France). Anti-Rac monoclonal anti-
body was purchased from Upstate Biotechnology. Anti-Cdc42 anti-
body was from Santa Cruz Biotechnology. Enhanced chemilumines-
cence (ECL) immunoblotting reagents were from Amersham
Pharmacia Biotech (Little Chalfont, UK). All other reagents were
obtained from Sigma unless otherwise indicated.
2.2. Platelet preparation and aggregation
Human platelets were isolated from concentrates obtained from the
local blood bank (Etablissement Franc°ais du Sang, Toulouse, France)
as described previously [15]. Brie£y, they were washed in a washing
bu¡er (pH 6.8) containing 140 mM NaCl, 5 mM KCl, 5 mM
KH2PO4, 1 mM MgSO4, 10 mM HEPES, 5 mM glucose, 0.35%
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bovine serum albumin (w/v). The same bu¡er plus 1 mM CaCl2 was
added to the ¢nal suspension and pH was adjusted to 7.4. In experi-
ments concerning PI 3-kinase product measurements, platelets were
labelled with 0.5 mCi/ml [32P]orthophosphate during 60 min in phos-
phate-free washing bu¡er (pH 6.5) at 37‡C. After stimulation lipids
were extracted and analysed as described previously [15]. Aggregation
was monitored by a turbidimetric method using a dual-channel Pay-
ton aggregometer (Payton Associates, Scarborough, ON, Canada)
with stirring at 900 rpm at 37‡C (7.5U108 platelets/ml).
2.3. Determination of activated cellular Rac and Cdc42
The amounts of activated cellular Rac and Cdc42 were determined
by precipitation with a fusion protein consisting of GST and the Rac-
binding domain from human PAK1 (amino acids 67^150) as de-
scribed [10]. Platelets were lysed in RIPA bu¡er (50 mM Tris, pH
7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium do-
decylsulphate (SDS), 500 mM NaCl, 10 mM MgCl2, 2.5 mM ethylene
glycol-bis(2-aminoethyl-ether)-N,N,NP,NP-tetraacetic acid (EGTA), 10
Wg/ml each of leupeptin and aprotinin, and 1 mM phenylmethylsul-
phonyl £uoride (PMSF)) and clari¢ed cell lysates were incubated with
GST-PAK1 beads (20^30 Wg) at 4‡C for 60 min. The beads were
washed four times with 50 mM Tris^HCl, pH 7.4, 10 mM MgCl2,
150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 5 mM EGTA and
5 Wg/ml each of leupeptin and aprotinin. The bead pellet was ¢nally
suspended in 15 Wl of Laemmli sample bu¡er, loaded on a 12% SDS^
PAGE, transferred to nitrocellulose membrane, and blotted for the
appropriate GTPase using speci¢c antibody against Rac or Cdc42.
2.4. Gel electrophoresis and immunoblotting
SDS^PAGE and immunodetections were performed as previously
described [15] using the relevant antibodies, peroxidase-conjugated
secondary antibody, and the ECL system.
3. Results
The activation of Rac was investigated using the GST-
PAK1 binding assay as previously described [10]. When hu-
man platelet lysate was incubated with GTPQS, Rac could
massively bind to GST-PAK1-coated beads, whereas no bind-
ing was detected when the lysate was incubated with GDPLS,
validating the technique in our model (Fig. 1A).
Triggering human platelets by thrombin or collagen led to a
very rapid and sustained activation of Rac reaching a max-
imum 30 s after addition of thrombin and 1 min after addition
of collagen and slowly decreasing thereafter (Fig. 1B,C).
Quanti¢cation of precipitated Rac by densitometric analysis
of immunoblots demonstrated that, under our experimental
conditions, the amount of activated Rac was twice higher in
thrombin-stimulated platelets compared to collagen-stimu-
lated cells (data not shown).
The Arg-Gly-Asp-Ser (RGDS) peptide known to block the
binding of ¢brinogen on integrin KIIbL3 was then used to
check whether Rac activation was dependent on integrin
KIIbL3 engagement occurring during platelet aggregation.
Rac activation by thrombin or by collagen was not a¡ected
by treatment of platelets by RGDS (Fig. 2A,B) which com-
pletely prevented platelet aggregation (Fig. 2, right panel).
Since RGD peptides may be partial integrin agonists [16],
we also used another KIIbL3 inhibitor, the synthetic agent
SR121566 [17]. Although this compound strongly inhibited
platelet aggregation, it did not a¡ect Rac activation upon
thrombin or collagen stimulation (Fig. 2). Moreover, an un-
related KIIbL3 blocking agent, antibody C7E3, had no signi¢-
cant e¡ect on Rac activation upon thrombin stimulation (not
shown). These data indicate that the rapid activation of Rac
observed upon thrombin or collagen stimulation occurs inde-
pendently of integrin engagement and aggregation.
The molecular mechanisms involved in the rapid activation
of Rac were then investigated. Both thrombin and collagen
are known to induce a rapid production of phosphoinositide-
derived second messengers such as inositol 1,4,5-trisphos-
phate, diacylglycerol and D3-phosphoinositides, which are
very important for platelet activation [15,18]. Interestingly,
the PLC inhibitor U-73122 strongly decreased the GTP load-
ing of Rac by thrombin or by collagen (Fig. 3A). The inactive
analogue U-73343 was without e¡ect (not shown). Con-
                                   
     
                                   
Fig. 1. Time course of Rac activation in human platelets stimulated
either by thrombin or by collagen. A: Anti-Rac immunoblot show-
ing the speci¢city of the interaction between Rac-GTP form and
GST-PAK1. Platelet lysates were incubated with either 100 WM
GDPLS or 100 WM GTPQS and the clari¢ed lysates were used for
the a⁄nity precipitation assay as described in Section 2. B,C: Time
course of Rac activation in thrombin- (B) or collagen- (C) stimu-
lated platelets. Human platelets (7.5U108 cells/ml) were stimulated
with thrombin (1 IU/ml) (B) or collagen (10 Wg/ml) (C). At the indi-
cated times, activation was stopped by addition of ice-cold 2U lysis
bu¡er. The resulting cell lysate was clari¢ed and used for the a⁄nity
precipitation assay for detection of activated Rac as described in
Section 2. The amount of Rac-GTP was quanti¢ed by densitometric
analysis and the results are expressed as percentage of maximal acti-
vation and are means þ S.E.M. of three to seven independent experi-
ments using distinct donors. A representative immunoblot of Rac
collected with the GST-PAK1 beads in thrombin- (B) or collagen-
(C) stimulated platelets is shown in the inset.
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versely, the activation of another member of the Rho family
which also interacts with PAK1 [10], Cdc42, occurred very
rapidly upon collagen addition (not shown), but did not re-
quire PLC activity (Fig. 3B). Indeed, the U-73122 compound,
which e⁄ciently inhibited the production of phosphatidic acid
(a re£ection of PLC activation in platelets [15]) as well as
platelet aggregation (not shown), did not signi¢cantly a¡ect
Cdc42 activation induced by collagen under conditions where
Rac was fully inhibited (Fig. 3B). Similar results were ob-
tained when thrombin was used as an agonist (not shown).
These results suggest a speci¢c role of PLC upstream of Rac
activation in human platelets and indicate that Cdc42 and
Rac are di¡erentially regulated in these cells.
The PKC inhibitor RO 31-8220 strongly inhibited platelet
aggregation induced by thrombin or collagen (Fig. 3C) but
did not a¡ect the activation of Rac (Fig. 3A). Conversely, Rac
activation by thrombin or collagen required an increase in the
free cytosolic Ca2 concentration. Indeed, EGTA, which che-
lates extracellular Ca2, only weakly a¡ected Rac activation
whereas addition of the intracellular Ca2 chelator 1,2-bis-(2-
aminophenoxy)ethane-N,N,NP,NP-tetraacetic acid tetrakis(ace-
toxymethyl ester) (BAPTA-AM) strongly impaired its activa-
tion by both agonists (Fig. 4A,B). It is noteworthy that GTP
loading of Cdc42 was not signi¢cantly a¡ected by BAPTA-
AM treatment (not shown) suggesting that, in contrast to
Rac, intracellular Ca2 was not required for its activation.
Prostaglandin I2 (PGI2), a potent inducer of cAMP produc-
tion through adenylate cyclase stimulation, is a strong nega-
tive regulator of platelet activation and is known to reduce the
Ca2 mobilisation induced by several agonists [18,19]. In
agreement, PGI2 strongly inhibited thrombin-induced activa-
tion of Rac (Fig. 4C). However, the fact that PGI2 signi¢-
Fig. 2. Thrombin- or collagen-induced activation of Rac is inde-
pendent of integrin engagement. Platelets were incubated either
without or with RGDS (500 WM) or SR121566 (3.5 WM) for 1 min
and were stimulated with thrombin (1 IU/ml) (A) or with collagen
(10 Wg/ml) (B). At the indicated times, Rac-GTP was precipitated
with GST-PAK1-coated beads and analysed as in Fig. 1. Results
are expressed as percentage of maximal activation and are mean-
s þ S.E.M. of three independent experiments when RGDS was used
as an antagonist or means þ S.D. of two independent experiments
when SR121566 was used. The e¡ect of RGDS (500 WM) or
SR121566 (3.5 WM) treatment on platelet aggregation induced by ei-
ther thrombin or collagen is shown on the right.
                     
             
                 
               
Fig. 3. Role of PLC activity but not of PKC activity in human
platelet Rac activation. A: Platelets were preincubated either with-
out or with U-73122 (10 WM) for 5 min or RO 31-8220 (5 WM) for
10 min and stimulated with thrombin (1 IU/ml) or with collagen
(10 Wg/ml). After 1 min, Rac-GTP was precipitated with GST-
PAK1-coated beads and analysed as indicated in Fig. 1. Results are
expressed as percentage of maximal activation and are mean-
s þ S.E.M. of three independent experiments. B: On the left, anti-
Rac immunoblot showing the involvement of PLC activity on Rac
activation induced by collagen (10 Wg/ml, 1 min). On the right, anti-
Cdc42 immunoblot of the same experiment showing that PLC activ-
ity is not required for Cdc42 activation. Results shown are represen-
tative of three independent experiments. C: The e¡ect of RO 31-
8220 (5 WM) treatment on platelet aggregation induced by either
thrombin or collagen is shown.
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cantly a¡ected the activation of Rac induced upon ionophore
A23187 addition (Fig. 4C, right panel) suggests that cAMP
can also regulate a factor downstream of calcium in the acti-
vation of Rac.
PI 3-kinase has been shown to play a role in the activa-
tion of Rac in several models [20,21]. To study the role of
PI 3-kinase in the activation of Rac by thrombin or colla-
gen, we inhibited this enzyme by 50 nM wortmannin. Under
these conditions the production of phosphatidylinositol
3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate
(PtdIns(3,4,5)P3) induced either by thrombin or by collagen
was inhibited by 93 þ 3% and 97 þ 5% (n = 3), respectively.
Fig. 5 shows that PI 3-kinase was not required for Rac acti-
vation in response to thrombin activation but was involved in
its activation through collagen receptors. Indeed, the extent of
GTP-Rac recovered with the GST-PAK1-coated beads was
signi¢cantly reduced in wortmannin-treated platelets (35% in-
hibition at 30 s, P6 0.05, n = 3 and 63% inhibition at 180 s,
P6 0.01, n = 3). The e¡ect of PI 3-kinase inhibition of GTP
charging of Rac was always stronger at the longest time of
activation suggesting that this lipid kinase is important for the
sustained activation of Rac. Similar results were obtained with
25 WM LY294002, another unrelated PI 3-kinase inhibitor
(not shown).
4. Discussion
Several lines of indirect evidence implicate the Rho family
GTPases in platelet activation pathways [6,7]. Recently Azim
et al. [9] provided the ¢rst direct measurement of platelet Rac
and Cdc42 activation in response to the thrombin receptor
PAR1 activating peptide. Their results con¢rm the temporal
link between GTPase activation, actin assembly and physio-
logical platelet responses. In the present study, we investigated
the mechanisms of Rac activation in response to thrombin, an
agonist acting through membrane receptors coupled to hetero-
trimeric G-proteins, and to collagen which is known to mobi-
lise a tyrosine kinase-dependent pathway. Both agonists in-
duced a very rapid activation of Rac that was dependent on
PLC activity. Interestingly, Cdc42, another GTPase of this
Fig. 4. Intracellular Ca2 is required for thrombin- and collagen-
mediated Rac activation. A,B: Platelets were preincubated either
with Ca2 (1 mM) or without Ca2 plus EGTA (5 mM) (+EGTA)
and stimulated for 1 min with 0.5 IU/ml thrombin (A) or with 10
Wg/ml collagen (B). They were also preincubated with BAPTA-AM
(30 WM) for 20 min in a bu¡er without Ca2 plus EGTA (5 mM)
(+EGTA+BAPTA) and were stimulated for 1 min with 0.5 IU/ml
thrombin (A) or with 10 Wg/ml collagen (B). Rac-GTP was precipi-
tated with GST-PAK1-coated beads and analysed as indicated in
Fig. 1. Results are expressed as percentage of maximal activation
and are means þ S.E.M. of three to ¢ve independent experiments.
C: E¡ect of prostaglandin I2 treatment of platelets on Rac activa-
tion. Platelets were preincubated either without or with 10 ng/ml
prostaglandin I2 (+PGI2) for 2 min and were stimulated with 1 IU/
ml thrombin during 1 min (left panel) or with 2 WM ionophore
A23187 during 30 s (right panel). Rac-GTP was precipitated with
GST-PAK1-coated beads and analysed as indicated in the legend to
Fig. 1.
Fig. 5. E¡ects of the PI 3-kinase inhibitor wortmannin on Rac acti-
vation in thrombin- and collagen-stimulated platelets. Platelets were
preincubated either without or with wortmannin (50 nM) for 15
min and stimulated with thrombin (1 IU/ml) (A) or with collagen
(10 Wg/ml) (B). At indicated times, Rac-GTP was precipitated with
GST-PAK1-coated beads and analysed as indicated in Fig. 1. Re-
sults are expressed as percentage of maximal activation and are
means þ S.E.M. of three independent experiments. *P90.05,
**P90.01.
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family also precipitated by the GST-PAK1 binding assay [10],
was not activated through PLC. This result is consistent with
the fact that overexpression of Rac or Cdc42 induces di¡erent
cell morphologies [4]. Moreover, their di¡erent cellular loca-
tion [9] suggests that they probably function in di¡erent ways
in human platelets. In contrast to Cdc42, Rac does not form
tight complexes with the actin cytoskeleton but rather inter-
acts with the plasma membrane where it may modulate phos-
phoinositide kinase activities [9]. Cdc42 can physically interact
with WASp family members to organise ARP2/3 complex-
mediated actin nucleation.
It has been shown that Gi-protein-coupled receptors, such
as chemoattractant fMLP receptor, can activate Rac [10^12]
but Gq/G11-protein-coupled receptors, such as bradykinin or
endothelin-1 receptor, are also able to stimulate this GTPase
[21^23]. The activation of Gq/PLCL by the thrombin receptor
PAR1 is a key event in platelet activation as GKq-de¢cient
platelets no longer respond to thrombin [24]. This suggests
that Gq/PLCL activation is required for Rac activation in-
duced by this agonist. In the case of collagen, PLCQ2 has
been shown to be activated by a mechanism involving the
tyrosine kinase Syk, downstream of GpVI, one of the major
collagen receptors at the platelet surface [14]. Besides the re-
cruitment of di¡erent PLC isoforms, one common denomina-
tor for these two agonists is the increase in intracellular Ca2
concentration by mobilisation of Ca2 from internal stores
and by in£ux of extracellular Ca2. We found that EGTA,
which chelates extracellular Ca2, had a weak inhibitory e¡ect
on Rac activation. Conversely, addition of BAPTA-AM,
which chelates intracellular Ca2, inhibited both thrombin-
and collagen-induced Rac activation. This is consistent with
the fact that PGI2, a potent activator of cAMP production,
inhibited the GTP loading of Rac. Indeed, cAMP, which is a
physiological mediator of platelet inhibition through activa-
tion of cAMP-dependent kinases, is known to inhibit Ca2
mobilisation in stimulated platelets [19,25]. However, the
fact that PGI2 signi¢cantly a¡ects Rac activation induced by
a rise in intracellular Ca2 in ionophore-treated platelets
strongly suggests that there are also cAMP-regulated inter-
mediate factors downstream of calcium in the activation of
Rac. The mechanism by which the intracellular Ca2 increase
results in Rac activation is unclear and is currently under
investigation. PLC activation and Ca2 mobilisation are im-
portant for platelet granule secretion [18]. A defect in media-
tor release through inhibition of granule secretion could ex-
plain, at least in part, the lack of Rac activation upon PLC
blockade or upon chelation of intracellular Ca2. However,
PKC, which is also involved in granule secretion, is not re-
quired for Rac activation. The release of thromboxane A2,
production of which requires the action of a cytosolic phos-
pholipase A2 regulated through increased cytosolic Ca2 [26],
may amplify the activation of Rac by thrombin, collagen or
even ionophore. Nevertheless, the very rapid activation of Rac
by thrombin or collagen suggests that the primary agonist
directly activates the GTPase. Although a regulation of an
exchange factor for Rac by Ca2 has not been described,
one cannot exclude such a possibility. Another hypothesis
involves calpain, a Ca2-dependent thiol protease present in
the cytosol of platelets. It was recently suggested that calpain
might be implicated in the regulation of Rac activation [27].
Although some evidence suggests that calpain may be acti-
vated directly by thrombin, its activation in platelets was orig-
inally shown to mainly occur after engagement of integrins
[28]. However, our results show that integrin engagement
was not required for thrombin- or collagen-induced Rac acti-
vation indicating that the early stimulation of Rac occurred
independently of integrin signalling. Although this result does
not exclude activation of Rac by integrin engagement at later
stages of platelet activation as in other cells during integrin-
mediated cell adhesion [27,29,30], it is not in favour of a role
of calpain in the early activation of Rac.
In various cell types, inhibition of PI 3-kinase was shown to
block GTP charging of Rac [20,21]. The Rac GTPase ex-
change factor VAV1 has a pleckstrin homology domain able
to interact with PtdIns(3,4,5)P3 and may account for this PI
3-kinase-dependent Rac activation. We also previously
showed that PtdIns(3,4,5)P3 can directly interact with Rac
[31] in vitro, a mechanism that may participate in the ad-
equate location of this GTPase. Here, we show that PI 3-ki-
nase is not required for Rac activation by thrombin but is
involved in the activation of Rac by collagen. GpVI, one of
the major collagen receptors, requires a PI 3-kinase for full
activation of PLCQ2 and calcium mobilisation [32]. Therefore,
it is likely that PI 3-kinase inhibition a¡ects the e⁄ciency of
PLC activation and the subsequent Ca2 mobilisation in col-
lagen-stimulated platelets. Alternatively, an exchange factor of
Rac such as VAV1, activation of which involves PI 3-kinase,
may be implicated in collagen-dependent Rac activation. Di-
rect interaction of Rac1 with PtdIns(3,4,5)P3 may also ac-
count for the adequate location of activated Rac and possibly
for its sustained activation [31].
Taken together, our data show that human platelet Rac is
rapidly activated by thrombin and collagen through a PLC
and Ca2 mobilisation-mediated mechanism. Conversely, the
rapid activation of Cdc42 is not sensitive to PLC inhibition.
This early activation of Rac is dependent neither on PKC
activity nor on integrin engagement and is inhibited by the
cAMP-producing physiologic mediator PGI2. Although the
molecular mechanism supporting the role of Ca2 in the acti-
vation of platelet Rac is still unknown, our data add new
information about the regulation of this GTPase in human
platelets.
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